Author: Admin

Developer

Research trovagene trov emerging as a leader in race to develop kras inhibitor

Posted on by Admin

Tuesday, January 28, 2020

Trovagene (TROV)

Emerging as a Leader in Race to Develop KRAS Inhibitor

Trovagene, Inc. is a clinical stage biotechnology company focused on the development of new therapeutics for hematology and oncology. The company’s clinical programs of Onvansertib (PLK1 inhibitor) include Phase 1b/2 study in AML, Phase 1b/2 study in mCRPC and Phase 1b/2 trial in KRAS-mutant colorectal cancer.

Cosme Ordonez, Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

We are resuming coverage of Trovagene after reassigning research coverage to a different analyst. The company yesterday released interim results from a Phase II clinical trial on the use of onvansertib for the treatment of metastatic colorectal cancer (CRC) patients carrying KRAS mutations. Onvansertib is an inhibitor of PLK1. In experimental models, the drug kills cancer cells harboring KRAS mutations…

Results were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) held in San Francisco on January 25, 2020. All five evaluable patients showed tumor regression (100% response), clinical benefit and a reduction in mutated KRAS burden. Five different KRAS mutations were targeted by onvansertib, which accounts for more than 90% of all…


Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research – Scorpio Bulkers (SALT) – Weakness Takes A Toll, But Rebound Expected

Posted on by Admin

Tuesday, January 28, 2020

Scorpio Bulkers (SALT)

Weakness Takes A Toll, But Rebound Expected

Scorpio Bulkers Inc is a shipping company based in Monaco. It owns and operates a fleet of modern mid to large-size dry bulk carriers which provide marine transportation for major bulks, which include iron ore, coal and grain and minor bulks which include bauxite, fertilizers and steel products internationally. In terms of its dead weight tonnage, its vessels are classified as Capesize, Kamsarmax and Ultramax, by the order of highest to lowest capacity, with Kamsarmax accounting for the highest revenue.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Adjusted 4Q2019 EBITDA of $20.0 million well below expectations. The main reasons for the negative variance were lower TCE rates, higher opex/G&A expenses and higher downtime for scrubber installations. Non-cash items include gain in STNG investment of $47 million and asset write down of $25 million.

Dry bulk market weakness accelerating into 1Q2020. The Baltic Panamax Index (BPI) average of 814 so far in 1Q2020 is down 52% from 1,461 in 4Q2019, and the Baltic Supramax Index (BSI) average of 542 so far in 1Q2020 is down 43% from 956 in 4Q2019. While IMO2020 adjustments to the indices have been partially to blame, the dry bulk market has clearly been weaker than expected and…


Get the full report on Channelchek desktop.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research – Trovagene (TROV) – Emerging as a Leader in Race to Develop KRAS Inhibitor

Posted on by Admin

Tuesday, January 28, 2020

Trovagene (TROV)

Emerging as a Leader in Race to Develop KRAS Inhibitor

Trovagene, Inc. is a clinical stage biotechnology company focused on the development of new therapeutics for hematology and oncology. The company’s clinical programs of Onvansertib (PLK1 inhibitor) include Phase 1b/2 study in AML, Phase 1b/2 study in mCRPC and Phase 1b/2 trial in KRAS-mutant colorectal cancer.

Cosme Ordonez, Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

We are resuming coverage of Trovagene after reassigning research coverage to a different analyst. The company yesterday released interim results from a Phase II clinical trial on the use of onvansertib for the treatment of metastatic colorectal cancer (CRC) patients carrying KRAS mutations. Onvansertib is an inhibitor of PLK1. In experimental models, the drug kills cancer cells harboring KRAS mutations…

Results were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) held in San Francisco on January 25, 2020. All five evaluable patients showed tumor regression (100% response), clinical benefit and a reduction in mutated KRAS burden. Five different KRAS mutations were targeted by onvansertib, which accounts for more than 90% of all…


Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research kratos defense security ktos are recent headlines a harbinger of things to come

Posted on by Admin

Monday, January 27, 2020

Kratos Defense & Security (KTOS)

Are Recent Headlines a Harbinger of Things to Come?

Kratos Defense & Security Solutions is a National Security technology provider with proprietary expertise in the area of unmanned aerial vehicles, electronics for missile defense systems, electronic warfare systems, satellite control and management systems and support services for emerging naval weapon systems. Commercial and state and local government revenues are about 25% of the total and comprise primarily of critical infrastructure monitoring and protection systems.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

More Positive Headlines.  In a recurring, almost weekly, theme, Kratos continues to see positive developments across a broad swath of its business. This past week, Kratos saw what we view as positive developments in both its Gremlins and Skyborg programs. While a leading independent, non-partisan policy research institute reaffirmed the need for Kratos’s products.

Successful Gremlins Test. DARPA’s Gremlins program completed the first flight test of its X-61A vehicle, built by Kratos. Kratos partners with Dynectics on this program which seeks to launch swarm UASs from multiple types of aircraft. The November test met all of its objectives. Another test…



Get the full report on Channelchek desktop.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Long Story Short: Impact Investing – Doing Well by Doing Good

Posted on by Admin

Impact Investing Challenges Traditional Methods for Promoting Social Good

(Note: companies that
could be impacted by the content of this article are listed at the base of the
story [desktop version]. This article uses third-party references to provide a
bullish, bearish, and balanced point of view; sources are listed after the
Balanced section.)

Impact investing is a strategy to invest in companies, organizations and funds with the intention to generate a positive social or environmental impact while earning a financial return.  Impact investing challenges the view that social and environmental issues should only be addressed by charitable donations, and that financial investments should focus only on returns.  The Global Impact Investing Network (GIIN) estimates that over 1,340 organizations managed US$502 billion in impact investing assets worldwide in 2018 and these numbers are expected to grow.  Alternative asset managers are starting funds dedicated to meeting environmental, social and governance targets as they seek to diversify product offerings, increase fees and meet growing demand from investors.

Research – Kratos Defense & Security (KTOS) – Are Recent Headlines a Harbinger of Things to Come?

Posted on by Admin

Monday, January 27, 2020

Kratos Defense & Security (KTOS)

Are Recent Headlines a Harbinger of Things to Come?

Kratos Defense & Security Solutions is a National Security technology provider with proprietary expertise in the area of unmanned aerial vehicles, electronics for missile defense systems, electronic warfare systems, satellite control and management systems and support services for emerging naval weapon systems. Commercial and state and local government revenues are about 25% of the total and comprise primarily of critical infrastructure monitoring and protection systems.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

More Positive Headlines.  In a recurring, almost weekly, theme, Kratos continues to see positive developments across a broad swath of its business. This past week, Kratos saw what we view as positive developments in both its Gremlins and Skyborg programs. While a leading independent, non-partisan policy research institute reaffirmed the need for Kratos’s products.

Successful Gremlins Test. DARPA’s Gremlins program completed the first flight test of its X-61A vehicle, built by Kratos. Kratos partners with Dynectics on this program which seeks to launch swarm UASs from multiple types of aircraft. The November test met all of its objectives. Another test…



Get the full report on Channelchek desktop.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Impact Investing Challenges Traditional Methods for Promoting Social Good

Posted on by Admin

Impact Investing Challenges Traditional Methods for Promoting Social Good

(Note: companies that
could be impacted by the content of this article are listed at the base of the
story [desktop version]. This article uses third-party references to provide a
bullish, bearish, and balanced point of view; sources are listed after the
Balanced section.)

Impact investing is a strategy to invest in companies, organizations and funds with the intention to generate a positive social or environmental impact while earning a financial return.  Impact investing challenges the view that social and environmental issues should only be addressed by charitable donations, and that financial investments should focus only on returns.  The Global Impact Investing Network (GIIN) estimates that over 1,340 organizations managed US$502 billion in impact investing assets worldwide in 2018 and these numbers are expected to grow.  Alternative asset managers are starting funds dedicated to meeting environmental, social and governance targets as they seek to diversify product offerings, increase fees and meet growing demand from investors.

Research onconova therapeutics ontx partnership dissolves greater china is added back to onconovas territories

Posted on by Admin

Friday, January 24, 2020

Onconova Therapeutics Inc. (ONTX)

Partnership dissolves – Greater China is Added Back to Onconova’s Territories

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Regained rights of rigosertib in greater China. On January 23, 2020, Onconova announced the termination of HanX license partnership due to HanX failing to make required payments under the terms of the agreement. The company has multiple other partnerships for rigosertib in various parts of the world including Knight Therapeutics for Canada, Specialised Therapeutics for Australia and New Zealand, Pint Pharma for Latin America and SymBio Pharmaceuticals for Japan and Korea. Given rigosertib prospects, we believe Onconova should be able to sign another partner in China.

Key Value Driving Catalysts in 2020. Although the INSPIRE study remains the company’s main focus, multiple inflection points are anticipated to generate value this year: i) presentation at the RAS-Targeted Drug Discovery Summit Europe on 25-27 February 2020 in Vienna, Austria; ii) submission of…



Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research sierra metals smts fourth quarter production results in line with expectations

Posted on by Admin

Friday, January 24, 2020

Sierra Metals (SMTS)

Fourth Quarter Production Results In Line with Expectations

Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico. Yauricocha is an underground polymetallic mine using the sublevel block caving and cut-and-fill mining methods. Bolivar is a copper-silver-zinc-gold underground mine using room-and-pillar mining method. The majority of the revenue is earned by selling of the mineral concentrates to its customers in Peru.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

SMTS reports fourth quarter production results. Compared with the prior year period, fourth quarter production of gold increased 69.2% to 3,615 ounces, silver increased 24.3% to 871 thousand ounces, lead production increased 24.9% to 9.9 million pounds, copper production increased 26.6% to 11.3 million pounds and

2020 Guidance.  At the midpoints of 2020 production guidance, Sierra expects 14.0%, 20.7% and 31.2% increases in silver, copper and zinc equivalent production relative to 2019. Production capacity is expected to increase from 8,350 tonnes per day at year-end 2019 to 9,500 tonnes per day by year-end 2020 and…


Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research – Onconova Therapeutics (ONTX): Partnership dissolves – Greater China is Added Back to Onconova’s Territories

Posted on by Admin

Friday, January 24, 2020

Onconova Therapeutics Inc. (ONTX)

Partnership dissolves – Greater China is Added Back to Onconova’s Territories

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Regained rights of rigosertib in greater China. On January 23, 2020, Onconova announced the termination of HanX license partnership due to HanX failing to make required payments under the terms of the agreement. The company has multiple other partnerships for rigosertib in various parts of the world including Knight Therapeutics for Canada, Specialised Therapeutics for Australia and New Zealand, Pint Pharma for Latin America and SymBio Pharmaceuticals for Japan and Korea. Given rigosertib prospects, we believe Onconova should be able to sign another partner in China.

Key Value Driving Catalysts in 2020. Although the INSPIRE study remains the company’s main focus, multiple inflection points are anticipated to generate value this year: i) presentation at the RAS-Targeted Drug Discovery Summit Europe on 25-27 February 2020 in Vienna, Austria; ii) submission of…



Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research – Sierra Metals (SMTS): Fourth Quarter Production Results In Line with Expectations

Posted on by Admin

Friday, January 24, 2020

Sierra Metals (SMTS)

Fourth Quarter Production Results In Line with Expectations

Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico. Yauricocha is an underground polymetallic mine using the sublevel block caving and cut-and-fill mining methods. Bolivar is a copper-silver-zinc-gold underground mine using room-and-pillar mining method. The majority of the revenue is earned by selling of the mineral concentrates to its customers in Peru.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

SMTS reports fourth quarter production results. Compared with the prior year period, fourth quarter production of gold increased 69.2% to 3,615 ounces, silver increased 24.3% to 871 thousand ounces, lead production increased 24.9% to 9.9 million pounds, copper production increased 26.6% to 11.3 million pounds and

2020 Guidance.  At the midpoints of 2020 production guidance, Sierra expects 14.0%, 20.7% and 31.2% increases in silver, copper and zinc equivalent production relative to 2019. Production capacity is expected to increase from 8,350 tonnes per day at year-end 2019 to 9,500 tonnes per day by year-end 2020 and…


Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research one stop systems inc- oss preliminary 4q and fy2019 revenues top expectations

Posted on by Admin

Thursday, January 23, 2020

One Stop Systems Inc. (OSS)

Preliminary 4Q and FY2019 Revenues Top Expectations

One Stop Systems Inc is US-based company which is principally engaged in designing, manufacturing, marketing high-end systems for high performance computing (HPC) applications. The company offers custom servers, compute accelerators, solid-state storage arrays and system expansion systems. The product line of the company includes GPU Appliances, GPU Expansion, GPUs and co-processors, Flash storage arrays, Flash storage expansion, Servers, Disk Arrays, Desktop computing appliances, accessories and parts. The company delivers high-end technology to customers through the sale of equipment and software for use on their premises or through remote cloud access to secure data centres housing technology.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Preliminary 2019 Revenues. OSS reported preliminary 2019 revenue of $58.3 million, above the high end of management’s previous $58 million guidance and above our $56.9 million projection. This is a 57% increase over 2018 revenue. Fourth quarter 2019 revenue is projected to be a record $18.4 million. Full year results are expected to be released in March. We will update our models then.

Growth Reflects Multiple Factors. The 2019 record growth reflects a combination of new design win revenue, acquisition related revenue, and ongoing growth at major customers. While acquisitions are always a wild card, we expect to see ongoing growth from major customers and…


Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research – One Stop Systems Inc. (OSS) – Preliminary 4Q and FY2019 Revenues Top Expectations

Posted on by Admin

Thursday, January 23, 2020

One Stop Systems Inc. (OSS)

Preliminary 4Q and FY2019 Revenues Top Expectations

One Stop Systems Inc is US-based company which is principally engaged in designing, manufacturing, marketing high-end systems for high performance computing (HPC) applications. The company offers custom servers, compute accelerators, solid-state storage arrays and system expansion systems. The product line of the company includes GPU Appliances, GPU Expansion, GPUs and co-processors, Flash storage arrays, Flash storage expansion, Servers, Disk Arrays, Desktop computing appliances, accessories and parts. The company delivers high-end technology to customers through the sale of equipment and software for use on their premises or through remote cloud access to secure data centres housing technology.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Preliminary 2019 Revenues. OSS reported preliminary 2019 revenue of $58.3 million, above the high end of management’s previous $58 million guidance and above our $56.9 million projection. This is a 57% increase over 2018 revenue. Fourth quarter 2019 revenue is projected to be a record $18.4 million. Full year results are expected to be released in March. We will update our models then.

Growth Reflects Multiple Factors. The 2019 record growth reflects a combination of new design win revenue, acquisition related revenue, and ongoing growth at major customers. While acquisitions are always a wild card, we expect to see ongoing growth from major customers and…


Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.